| scholarly article | Q13442814 |
| P50 | author | Leonidas Stamatatos | Q89197121 |
| P2093 | author name string | Miroslaw K Gorny | |
| Susan Zolla-Pazner | |||
| Barbara Volsky | |||
| Constance Williams | |||
| Kathy Revesz | |||
| Xiao-Hong Wang | |||
| Sandra Cohen | |||
| Robert Staudinger | |||
| P2860 | cites work | Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1 | Q24645530 |
| Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody | Q27759364 | ||
| Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. | Q28646878 | ||
| Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody | Q29618366 | ||
| Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 | Q29619512 | ||
| Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins | Q33653001 | ||
| Neutralization Profiles of Primary Human Immunodeficiency Virus Type 1 Isolates in the Context of Coreceptor Usage | Q33783714 | ||
| An Envelope Modification That Renders a Primary, Neutralization-Resistant Clade B Human Immunodeficiency Virus Type 1 Isolate Highly Susceptible to Neutralization by Sera from Other Clades | Q33784679 | ||
| Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. | Q33785510 | ||
| Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. | Q33809112 | ||
| Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate | Q33811940 | ||
| Generation of human monoclonal antibodies to human immunodeficiency virus | Q33841011 | ||
| Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein | Q34097650 | ||
| Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. | Q34145199 | ||
| Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection | Q34317025 | ||
| The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. | Q34342352 | ||
| Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. | Q35839973 | ||
| Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. | Q35857331 | ||
| Constitutive cell surface association between CD4 and CCR5. | Q36397946 | ||
| Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. | Q36623941 | ||
| Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop | Q36651187 | ||
| Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. | Q36890344 | ||
| The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. | Q36954472 | ||
| Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody | Q37603996 | ||
| Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. | Q39143635 | ||
| V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies | Q39592261 | ||
| Induction and characterization of neutralizing antibodies against a human immunodeficiency virus type 1 primary isolate | Q39603619 | ||
| Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses. | Q40038787 | ||
| Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4 binding site in the fourth conserved region | Q40061779 | ||
| Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
| An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection | Q41679452 | ||
| Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody | Q44781672 | ||
| V3-Specific Polyclonal Antibodies Affinity Purified from Sera of Infected Humans Effectively Neutralize Primary Isolates of Human Immunodeficiency Virus Type 1 | Q45734123 | ||
| Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: isolation of a neutralization escape variant | Q45756890 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| Prevention of HIV infection by passive immunization with HIV immunoglobulin | Q47571809 | ||
| Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120 | Q72067428 | ||
| Neutralization of animal viruses | Q72886254 | ||
| Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120 | Q74618553 | ||
| Evidence for CD4-enchanced signaling through the chemokine receptor CCR5 | Q78806608 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| P304 | page(s) | 5232-5237 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles | |
| P478 | volume | 79 |
| Q34047445 | A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals |
| Q38342167 | Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop |
| Q34562259 | Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial |
| Q35024202 | Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo |
| Q38030235 | Antibody–antigen pair probed by combinatorial approach and rational design: Bringing together structural insights, directed evolution, and novel functionality |
| Q37547245 | Antigenic properties of the HIV envelope on virions in solution |
| Q36559838 | Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion |
| Q34645502 | B cell responses to HIV-1 infection and vaccination: pathways to preventing infection |
| Q38025633 | Basic research in HIV vaccinology is hampered by reductionist thinking |
| Q35077716 | Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16. |
| Q35689608 | Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Virions |
| Q29547347 | Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target |
| Q36131738 | Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein |
| Q91812746 | Broadly Neutralizing Antibodies against HIV: Back to Blood |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q34302085 | Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants |
| Q38631979 | Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities. |
| Q37072702 | Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. |
| Q37003083 | Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer |
| Q36434294 | Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites |
| Q27663325 | Conserved structural elements in the V3 crown of HIV-1 gp120 |
| Q43215260 | Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers |
| Q37445549 | Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins |
| Q27666407 | Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1 |
| Q34907398 | Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. |
| Q37033294 | Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection |
| Q27681527 | Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV |
| Q38764547 | Germline-targeting immunogens |
| Q33552488 | HIV-1 and influenza antibodies: seeing antigens in new ways |
| Q33947008 | HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1 |
| Q36132728 | HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. |
| Q37484124 | HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study |
| Q30355260 | HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development |
| Q36076117 | Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein |
| Q28602877 | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies |
| Q39845715 | Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins |
| Q40296420 | Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design |
| Q47566053 | Identification of novel structural determinants in MW965 Env that regulate the neutralization phenotype and conformational masking potential of primary HIV-1 isolates |
| Q38220506 | Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies |
| Q29617377 | Immune-correlates analysis of an HIV-1 vaccine efficacy trial |
| Q34164923 | Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies |
| Q33725718 | In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 |
| Q34983331 | Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120. |
| Q35102328 | Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies |
| Q35647772 | Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer |
| Q35043547 | Is developing an HIV-1 vaccine possible? |
| Q37370393 | Isolation of HIV-1-reactive antibodies using cell surface-expressed gp160Δc(BaL.). |
| Q37910841 | Limitations to the structure‐based design of HIV‐1 vaccine immunogens |
| Q28477253 | Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies |
| Q27651385 | Molecular architecture of native HIV-1 gp120 trimers |
| Q28728517 | Monoclonal Antibodies to the V2 Domain of MN-rgp120: Fine Mapping of Epitopes and Inhibition of α4β7 Binding |
| Q36404752 | Monoclonal antibody m18 paratope leading to dual receptor antagonism of HIV-1 gp120. |
| Q39845890 | Multiple tandem copies of conserved gp41 epitopes incorporated in gag virus-like particles elicit systemic and mucosal antibodies in an optimized heterologous vector delivery regimen |
| Q36315745 | Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. |
| Q40909337 | Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection |
| Q41924059 | Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. |
| Q26861148 | Nonhuman primate models for HIV/AIDS vaccine development |
| Q37668399 | Novel HIV vaccine strategies: overview and perspective |
| Q34309493 | Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q34742533 | Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop |
| Q41816066 | Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1 |
| Q36974754 | Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. |
| Q33614461 | Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites |
| Q39610645 | Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4 |
| Q35603504 | Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. |
| Q37448281 | Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits |
| Q34225659 | Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine |
| Q35635163 | Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection |
| Q38046828 | Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. |
| Q34397758 | Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies |
| Q34648342 | Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces cross-neutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. |
| Q34279140 | Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure |
| Q37554149 | Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking |
| Q34415389 | Specificity of the autologous neutralizing antibody response |
| Q27667819 | Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120 |
| Q27680810 | Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12 |
| Q42707235 | Structural Comparison of HIV-1 Envelope Spikes with and without the V1/V2 Loop |
| Q27644478 | Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 |
| Q37409244 | Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site |
| Q28071559 | Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory |
| Q34987048 | Structure-based Vaccine Design in HIV: Blind Men and the Elephant? |
| Q35196671 | Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design |
| Q34499013 | Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity |
| Q34485260 | The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter |
| Q38243948 | The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development |
| Q34303849 | The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. |
| Q33883936 | The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner |
| Q30152923 | The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel |
| Q37789346 | The humoral response to HIV-1: new insights, renewed focus. |
| Q42181481 | Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops |
| Q34583767 | Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positio |
| Q37221499 | Tyrosine-sulfated V2 peptides inhibit HIV-1 infection via coreceptor mimicry. |
| Q93150656 | Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV |
Search more.